The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Subscribe To Our Newsletter & Stay Updated
